Glenmark Introduces GLIPIQ to Expand Access to Advanced Diabetes Care in India
Glenmark Pharmaceuticals has launched GLIPIQ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), with a clear focus on improving affordability and access to advanced therapies. The product has received approval from the Central Drugs Standard Control Organisation (CDSCO) following a Phase III clinical study conducted in India to evaluate its efficacy … Read more